Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

280.55USD
10:49am EDT
Change (% chg)

$0.86 (+0.31%)
Prev Close
$279.69
Open
$277.14
Day's High
$282.36
Day's Low
$276.65
Volume
253,129
Avg. Vol
1,769,842
52-wk High
$370.57
52-wk Low
$244.28

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $59,016.81
Shares Outstanding(Mil.): 211.01
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 14.31 28.66 32.90
EPS (TTM): 19.54 -- --
ROI: 20.73 13.20 12.74
ROE: 32.41 14.95 14.64

Samsung BioLogics said JV partner Biogen to exercise option by late June

SEOUL, May 18 Samsung BioLogics said on Friday that its joint venture partner Biogen would exercise its call option to increase its stake to 50 pct minus one share in Samsung Bioepis.

May 17 2018

Accounting concerns wipe $6 billion off Samsung BioLogics market value

SEOUL South Korean biotech drug manufacturer Samsung BioLogics Co Ltd lost almost $6 billion in market value on Wednesday in its biggest intra-day share drop, after the country's financial watchdog said it breached accounting rules.

May 02 2018

UPDATE 3-Accounting concerns wipe $6 bln off Samsung BioLogics market value

* Financial watchdog gives preliminary notice to co on measures

May 02 2018

BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab

* BIOGEN AND NEURIMMUNE ANNOUNCE OPTION EXERCISE FOR ALZHEIMER'S DISEASE INVESTIGATIONAL TREATMENT ADUCANUMAB

May 01 2018

BRIEF-Biogen CEO Michel Vounatsos' Total Compensation For 2017 Was $13.7 Million

* BIOGEN SAYS CEO MICHEL VOUNATSOS' TOTAL COMPENSATION FOR 2017 WAS $13.7 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KjjpbG) Further company coverage:

Apr 27 2018

Biogen's revenue misses as Spinraza sales disappoint

Drugmaker Biogen Inc's quarterly revenue missed analysts' estimates on Tuesday as it had disappointing sales of its promising drug Spinraza to treat spinal muscular atrophy because fewer new patients used the expensive treatment.

Apr 24 2018

UPDATE 3-Biogen's revenue misses as Spinraza sales disappoint

* Biogen shares pare losses (Adds conference call, analysts comments; updates shares)

Apr 24 2018

Biogen quarterly profit jumps on higher Spinraza sales

April 24 Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza.

Apr 24 2018

BRIEF-Biogen Reports Quarterly Revenues Of $3.1 Billion

* QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR

Apr 24 2018

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

Apr 20 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.76 +0.85
Pfizer Inc. (PFE.N) $35.85 +0.13
Novartis AG (NOVN.S) CHF76.26 -0.42
Merck & Co., Inc. (MRK.N) $59.24 +0.79
Roche Holding Ltd. (ROG.S) CHF219.05 -4.85
Roche Holding Ltd. (RO.S) CHF223.20 -5.60
Bayer AG (BAYGn.DE) €102.52 -2.52
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.04 -0.33
GlaxoSmithKline plc (GSK.L) 1,510.53 +1.33

Earnings vs. Estimates